Sourcing & Management of Health Products - Updates

Opportunity for Evaluation of Selected Medicines - Covid-19 Pharmaceutical Products

02 February 2022

The Global Fund is inviting manufacturers of Covid-19 pharmaceutical products namely:

  • Molnupiravir 200mg capsules for oral administration
  • Nirmatrelvir 150 mg tablets (2) plus ritonavir 100 mg tablet (1), co-packaged for oral administration

to submit an expression of interest to have their product evaluated by the Expert Review Panel for Pharmaceutical Products.

Detailed information about the review process and submission requirements for this Ad-Hoc ERP opportunity can be found in the document below.

Once the expression of interest has been received, the Expert Review Panel will be responsible for reviewing and judging its eligibility and whether to perform a risk-benefit assessment of the product submitted.

Please note that this is an open invitation as for all Ad-hoc ERP review; therefore no deadline for submission is envisaged at present.

  • Invitation to Covid-19 Pharmaceutical Products Manufacturers to Submit an Expression of Interest for Product Evaluation by the Global Fund Expert Review Panel for Pharmaceutical Products (GF/ERP/Ad-Hoc/02-2022)
    download in English

***

The Global Fund is inviting manufacturers of COVID-19 pharmaceutical products (namely Molnupiravir 200mg capsules for oral administration) to submit an expression of interest to have their product evaluated by the Expert Review Panel for Pharmaceutical Products.

Detailed information about the review process and submission requirements for this Ad-Hoc ERP opportunity can be found in the document below.

Once the expression of interest has been received, the Expert Review Panel will be responsible for reviewing and judging its eligibility and whether to perform a risk-benefit assessment of the product submitted.

Please note that this is an open invitation as for all Ad-hoc ERP review ; therefore no deadline for submission is envisaged at present.

  • Invitation to COVID-19 Pharmaceutical Products Manufacturers to Submit an Expression of Interest for Product Evaluation by the Global Fund Expert Review Panel for Pharmaceutical Products (GF/ERP/Ad-Hoc/12-2021)
    download in English